8 January 2021 - The UK’s NICE has turned down Bristol Myers Squibb’s immunotherapy Opdivo (nivolumab) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum-based chemotherapy.

In draft guidance, NICE said evidence collected in the clinical trial and through its own Cancer Drugs Fund showed that people with SCCHN live longer when treated with Opdivo than with one of three possible treatments in the comparator arm.

Read Pharma Times article